Business & M&A
The latest in business & m&a for medical-aesthetics practice owners.
Business & M&A Steel Partners Bids $16.75/Share for InMode — What a Hostile Takeover Means for Device Buyers
A major shareholder's unsolicited offer upends the aesthetic-device market's M&A calculus.
Business & M&A L'Oréal Raises Galderma Stake to 20% — What Luxury-Goods Capital Means for Aesthetic Pricing
The beauty conglomerate deepens its commitment to the aesthetic-injectables and device maker.
Business & M&A Sisram Medical Restructures DAXXIFY China Deal With Fosun — Supply Chain Shift Signals Market Consolidation
The toxin maker reshuffles its Asia-Pacific distribution as competition intensifies.
Business & M&A L'Oréal Raises Galderma Stake to 20% — Strategic Beauty-Pharma Convergence Play
Luxury conglomerate deepens investment in aesthetics company; signals confidence in injectables and device market.
Business & M&A Sisram Medical Restructures DAXXIFY China Deal With Fosun — Botulinum Toxin Strategy Shifts
Aesthetic device company revamps toxin distribution partnership; signals market complexity in China toxin licensing.
Business & M&A Steel Partners Offers $16.75/Share for InMode — Rival Bid Challenges CEO Buyout
Unsolicited cash offer from major shareholder tops competing proposal; device maker's board faces competing valuations.
Business & M&A Steel Partners Bids $16.75/Share for InMode — What the Takeover Battle Means for Your Device Choices
A rival cash offer tops the CEO-led buyout, signaling consolidation pressure across the RF microneedling and energy-device market.
Business & M&A L'Oréal Boosts Galderma Stake to 20% — Strategic Beauty-Industry Backing Signals Long-Term Commitment
L'Oréal's increased investment in Galderma reinforces the aesthetics company's position and may accelerate product launches.
Business & M&A Sisram Medical Restructures DAXXIFY China Deal With Fosun Unit — Supply Chain Complexity Deepens
A revamped distribution arrangement for Daxxify in China reflects ongoing supply and regulatory challenges in the world's second-largest aesthetics market.
Business & M&A Steel Partners Bids $16.75/Share for InMode — What a Contested Takeover Means for Device Buyers
Unsolicited offer challenges CEO-led buyout; device consolidation accelerates.
Business & M&A AbbVie Allergan Aesthetics Files Material Event — Botox and Juvéderm Pricing or Loyalty Changes Likely
SEC filing signals potential shifts to Allē program or product pricing affecting practice margins.
Business & M&A Evolus Files Material Event on Jeuveau Loyalty Program — Pricing and Rebate Moves Signal Market Pressure
Evolus Rewards program changes suggest competitive response to AbbVie and Galderma toxin pricing.
Business & M&A Steel Partners Bids $16.75 Per Share for InMode — Unsolicited Offer Challenges CEO Buyout
Activist investor Steel Partners launches rival cash offer for the RF microneedling and energy-device maker.
Business & M&A InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Device Market
InMode shares rose on an unsolicited acquisition proposal, signaling continued PE and strategic interest in high-margin aesthetic device makers.
Business & M&A AbbVie Files Material 8-K on Allergan Aesthetics — Pricing or Rebate Shift Likely Ahead
AbbVie disclosed a material event related to Allergan Aesthetics, signaling potential changes to Botox/Juvéderm pricing or Allē loyalty terms.
Business & M&A L'Oréal Boosts Galderma Stake to 20% — Strategic Bet on Aesthetics and Skincare Convergence
L'Oréal increased its ownership in Galderma, signaling confidence in the dermatology and aesthetics player despite recent regulatory setbacks.
Business & M&A InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Energy-Device Space
PE or strategic buyer circles InMode; device M&A cycle accelerates.
Business & M&A AbbVie Files Material Event on Allergan Aesthetics — Pricing or Rebate Move Likely Incoming
SEC 8-K signals potential changes to Botox/Juvéderm economics; monitor Allē terms closely.
Business & M&A InMode Confirms Receipt of Unsolicited Takeover Proposal — Strategic Interest Signals Market Consolidation
The Israeli energy-device maker is exploring a potential acquisition, reflecting ongoing PE and strategic buyer interest in aesthetic-device platforms.
Business & M&A InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
CEO-led group bids for InMode; signals continued PE and strategic interest in energy-device consolidation.
Business & M&A Evolus Files Material Events — Jeuveau Pricing and Evolus Rewards Program Under Strategic Review
SEC filings suggest competitive moves or program restructuring for Evolus' toxin and loyalty platform.
Business & M&A AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing and Rebate Moves Signal Margin Pressure
SEC 8-K filings from AbbVie suggest material changes to Allergan Aesthetics' pricing or loyalty program structure.
Business & M&A L'Oréal Increases Stake in Galderma to 20% — Consolidation Pressure Mounts in Aesthetics
Luxury conglomerate deepens investment in filler and toxin competitor, signaling confidence in aesthetic injectables market.
Business & M&A AbbVie Allergan Aesthetics Files Multiple Material Events — Botox/Juvéderm Pricing or Allē Loyalty Shifts Imminent
Three SEC 8-K filings over four months signal repeated strategic moves affecting toxin and filler economics.
Business & M&A L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Premium Filler Market
Beauty conglomerate deepens commitment to Galderma, signaling confidence in Restylane and Sculptra franchises amid injectable consolidation.
Business & M&A Evolus Files Material Event — Jeuveau Pricing or Loyalty Program Shift Likely
SEC 8-K signals strategic move in neuromodulator market; watch Evolus Rewards structure and per-unit economics.
Business & M&A AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Adjustments Likely
Bellwether filings signal margin pressure and loyalty-program recalibration across the injector base.
Business & M&A Evolus Files Material Event — Jeuveau Loyalty Program Signals Aggressive Medspa Push
Evolus Rewards program expansion suggests competitive pricing moves in the neuromodulator market targeting independent practices.
Business & M&A AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Moves Imminent
Three SEC filings in four months signal competitive pressure on Allergan Aesthetics' core injectable margins.
Business & M&A Allergan Aesthetics Files Multiple Material Events — Pricing and Rebate Moves Signal Margin Pressure
Three SEC filings from AbbVie's Allergan Aesthetics suggest significant pricing or rebate adjustments affecting the Botox/Juvéderm/Allē ecosystem.
Business & M&A Evolus Files Multiple Material Events — Jeuveau Pricing Strategy Intensifies
Evolus's SEC filings suggest aggressive commercial moves in the neuromodulator market, targeting medspa practices directly.
Business & M&A AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing and Rebate Moves Signal Margin Pressure Across Injectable Market
Three SEC 8-K filings from AbbVie in four months suggest active repricing or loyalty program adjustments in Botox and Juvéderm portfolios.
Business & M&A Evolus Files Multiple Material Events — Jeuveau Pricing and Loyalty Program Moves Target Medspa Market Share
Three Evolus SEC filings suggest aggressive repricing or rebate restructuring in Jeuveau and Evolus Rewards to compete for injectable volume.
Business & M&A AbbVie's Allergan Aesthetics Files Multiple Material Events — Pricing and Rebate Moves Ahead
Three SEC 8-K filings signal strategic shifts in Botox/Juvéderm pricing or Allē loyalty structure; injector margins under pressure.
Business & M&A Evolus Files Multiple Material Events — Jeuveau Competitive Moves Underway
Evolus's SEC filings suggest strategic shifts in Jeuveau pricing or Evolus Rewards loyalty program; price-war dynamics accelerating.
Business & M&A AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing or Rebate Moves Likely Ahead
Three SEC 8-K filings from AbbVie signal material changes to Allergan Aesthetics' business; Allē loyalty terms may be in flux.
Business & M&A Evolus Files Multiple Material Events — Jeuveau Competitive Pricing Strategy in Motion
Evolus has filed three SEC 8-Ks; the company is likely adjusting Jeuveau pricing or Evolus Rewards rebate terms to capture market share from Allergan.
Business & M&A Medspa Franchise vs Independent Practice: Cost, Control, and Unit Economics
Franchises offer turnkey systems and brand leverage; independents keep margin and autonomy. Here's what the real economics look like.
Business & M&A Should Your Medspa Have a Membership Program? Models, Metrics, and Revenue Impact
Membership programs convert one-time buyers into predictable recurring revenue—but only if you structure them right. Here's what the math actually shows.
Business & M&A How to Market a Medspa: High-Converting Channels and Real Unit Economics
The channels that drive patient acquisition, retention, and referral for independent medspas—with the metrics that matter to your P&L.
Business & M&A How Much Revenue Can One MedSpa Treatment Room Generate?
The math on treatment-room revenue depends on utilization rate, service mix, and pricing—here's how to model your own.
Business & M&A How Much Does It Cost to Open a Medspa? Real Buildout, Device, and Staffing Numbers
A breakdown of the actual capital required: facility, equipment, licensing, staff, and working capital for a standalone aesthetic practice.
Business & M&A Boulevard vs Aesthetic Record vs PatientNow: Which Medspa Software Fits Your Practice
Three leading platforms dominate medspa software—here's how they differ in pricing, features, and which practices they actually serve best.
Business & M&A What It Takes to Open a Medical Spa: Licensing, Medical Director, Ownership, and Capital Requirements
The regulatory and financial foundation for launching a medspa depends on state law, medical director oversight, and whether you're a clinician or investor.
Business & M&A How to Price Lip Filler at Your MedSpa: Cost Inputs, Market Rates, and Packaging Strategy
Build a defensible lip filler pricing model by understanding COGS, regional demand, and whether to sell by syringe, unit, or package.
Business & M&A Medspa Profit Margins: What's Normal by Service Line
Gross margins for injectables, laser, and energy devices vary widely—here's what healthy medspas actually achieve and why.
Business & M&A Botox Cost Per Unit and Profit Margin: The Real Economics for Medspa Owners
Understand wholesale acquisition costs, retail pricing benchmarks, and how rebate programs affect your bottom line.
Business & M&A InMode Receives Unsolicited $16.20-Per-Share Acquisition Proposal — Device Consolidation Accelerates
CEO-led group bids for InMode; valuation signals market appetite for RF microneedling and energy-device consolidation.
Business & M&A Med Spa Valuation and Exit Basics: What Makes a Practice Worth Buying
Whether you ever sell or not, understanding what makes a practice valuable to a buyer is a useful lens — because the things that raise your value are mostly the things that make you well-run.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.